Cutting Edge Cancer Care 

Dr. Lilker specializes in Foot Care in the Cancer Patient. He is the preferred Foot Doctor for Memorial Sloan Kettering Cancer Center in New York City.  

JAPMA Article.jpg

Cancer is one of the leading causes of mortality and morbidity worldwide. Recent improved therapies have resulted in more patients surviving cancer and living longer. Despite these advances, the majority of patients will develop adverse events from anticancer therapies.

 

Foot alterations, including nail toxicities, hand-foot syndrome, edema, xerosis, hyperkeratosis, and neuropathy, are frequent among cancer patients. These untoward conditions may negatively impact quality of life, and in some cases may result in the interruption or discontinuation of cancer treatments. Appropriate prevention, diagnosis, and management of podiatric adverse events are essential to maintain foot function and health-related quality of life, both of which are critical for the care of cancer patients and survivors. This article shows results related to complaint and impact on quality of life of the Oncology Foot Care program and reviews publications specific to podiatric adverse events related to cancer treatments.

 Research &  Publications: 

Published: November 2018 – Journal of the American Podiatric Medical Association (JAPMA)

  • Mario E Lacouture MD, David J Kopsky MD, Raphael Lilker DPM, Fiona Damstra MD, Mecheline HM van der Linden PhD, Azael Freites-Martinez MD, Mischa PM Nagel. “Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors”

In Progress:

  • Mischa PM Nagel, Monica Dhawan MD, Raphael Lilker DPM, Christine B. Boers-Doets MD. “Therapeutic footwear improves the functional mobility and quality of life of patients with chemotherapy-induced hand-foot syndrome:
    Results of a pilot study”